Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. COSMOS Pharmaceutical's pretax income for the
three
months ended in Feb. 2026 was $77 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Feb. 2026 was $288 Mil.
COSMOS Pharmaceutical's pretax margin was 4.38%.
During the past 13 years, COSMOS Pharmaceutical's highest Pretax Margin was 5.31%. The lowest was 3.49%. And the median was 4.41%.
During the past 13 years, COSMOS Pharmaceutical's highest Pretax Margin was 5.31%. The lowest was 3.49%. And the median was 4.41%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical Pre-Tax Income Related Terms
COSMOS Pharmaceutical Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical Pre-Tax Income Competitor Comparison
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical Pre-Tax Income vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $288 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a Pre-Tax Income of $288 Mil as of Feb. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on COSMOS Pharmaceutical and its competitors.
Is COSMOS Pharmaceutical's Pre-Tax Income too high?
COSMOS Pharmaceutical's current Pre-Tax Income is $288 Mil. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Pre-Tax Income compare to competitors?
COSMOS Pharmaceutical's Pre-Tax Income of $288 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Healthcare Providers & Services company?
A good Pre-Tax Income depends on the Healthcare Providers & Services industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on COSMOS Pharmaceutical and its competitors. COSMOS Pharmaceutical's current Pre-Tax Income is $288 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.99, compared to a current price of $37.06 — trading 28.7% below its estimated fair value. The current Pre-Tax Income is $288 Mil. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Pre-Tax Income is $288 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.7% below its estimated GF Value™ of $51.99.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
Pre-Tax Income: $288 Mil
GF Value™: $51.99 vs. price of $37.06 (28.7% below fair value)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
